Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study of Durvalumab (Medi4736) and Tremelimumab Following Radioembolization in Patients With Unresectable Locally Advanced Hepatocellular Carcinoma

NCT04605731 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT04605731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04605731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study of Durvalumab (Medi4736) and Tremelimumab Following Radioembolization in Patients With Unresectable Locally Advanced Hepatocellular Carcinoma
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 3, 2021
Completion date
February 23, 2027
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bclc stage b hepatocellular carcinoma, bclc stage c hepatocellular carcinoma, locally advanced hepatocellular carcinoma, stage iii hepatocellular carcinoma ajcc v8, stage iiia hepatocellular carcinoma ajcc v8, stage iiib hepatocellular carcinoma ajcc v8, stage iv hepatocellular carcinoma ajcc v8, stage iva hepatocellular carcinoma ajcc v8, stage ivb hepatocellular carcinoma ajcc v8, unresectable hepatocellular carcinoma